Jupiter Topco LLC Buys Shares of 15,500 Dianthus Therapeutics, Inc. $DNTH

Jupiter Topco LLC purchased a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 15,500 shares of the company’s stock, valued at approximately $1,511,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ABS Investment Management LLC bought a new stake in shares of Dianthus Therapeutics in the second quarter worth $194,960,000. EFG International AG bought a new position in Dianthus Therapeutics in the second quarter valued at $49,000. Nicholas Investment Partners LP acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $18,206,000. Legal & General Group Plc acquired a new stake in Dianthus Therapeutics in the 2nd quarter valued at $3,152,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Dianthus Therapeutics during the 2nd quarter worth about $6,125,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial restated a “strong-buy” rating and issued a $131.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Finally, Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.92.

Insider Buying and Selling

In related news, SVP Adam M. Veness sold 30,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the sale, the senior vice president owned 30,000 shares of the company’s stock, valued at $2,424,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The shares were sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the transaction, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 283,678 shares of company stock valued at $29,672,400 in the last ninety days. 3.02% of the stock is currently owned by company insiders.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $108.10 on Friday. The company’s 50-day moving average is $105.23 and its 200-day moving average is $89.08. The firm has a market capitalization of $5.91 billion, a PE ratio of -26.05 and a beta of 1.24. Dianthus Therapeutics, Inc. has a fifty-two week low of $24.49 and a fifty-two week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. As a group, analysts expect that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.